


of Deposit January 31, 2001

BY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH  
UNITED STATES POSTAL SERVICE BY EXPRESS MAIL POST OFFICE  
ADDRESSEE SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED  
AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR  
PATENT & TRADEMARK OFFICE  
WASHINGTON, DC, 20231.

by Ellen Fiala

OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)

ATURE OF PERSON MAILING PAPER OR FEE)



#3

0400  
12-28-00  
AM-100151-P1  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****In re Patent Application of: J. P. Yardley et al.****Serial No.:** 09/706,683**Examiner:****Filed:** November 3, 2000**Group:****For:** Branched Adamantyl and Noradamantryl Aryl and  
Aralkylpiperazines with Serotonin 5-HT1A Activity**Assistant Commissioner of Patents  
Washington, D.C. 20231****BEST AVAILABLE COPY****INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)****Sir:**

With respect to the subject matter of the above-identified application, applicants have become aware of the following references which may have relevance to the examination of the invention claimed:

U.S. Patent 3,717,634, Wu (1973)

U.S. Patent 4,001,223, Sugimoto (1977)

U.S. Patent 4,202,898, Depoortere (1980)

U.S. Patent 4,797,489, Abou-Gharbia (1989)

U.S. Patent 4,873,331, Childers (1989)

U.S. Patent 4,882,432, Abou-Gharbia (1989)

U.S. Patent 4,988,814, Abou-Gharbia (1991)

U.S. Patent 5,340,812, Cliffe (1994)

U.S. Patent 5,380,725, Abou-Gharbia (1995)

U.S. Patent 5,482,940, Abou-Gharbia (1996)


U.S. Patent 5,486,518, Yardley (1996)

- U.S. Patent 5,519,025, Yardley (1996)
- EP 0 512 755, Cliffe 1992)
- GB 2 218 988, Abou-Gharbia (1989)
- Rasmussen, K., *Annual Reports in Med. Chemistry*,  
Vol. 30, Chapter 1, Academic Press, NY, pp. 1-9 (1995)
- Schaus, J.M., *Annual Reports in Med. Chemistry*,  
Vol. 33, Chapter 3., Academic Press, NY, pp. 21-30 (1998)
- Holt, W.F. et al., *Neuroprotection in CNS Diseases*, Marcel  
Dekker Inc, NY pp. 87-119 (1997)
- Engelsen, B. et al., *Neurotoxicity of Excitatory Amino-Acids*,  
Raven Press, NY pp. 311-322 (1990)
- Ince et al., *Rev. Contemp. Pharmacother.*, 8, 195-212 (1997)
- Meldrum, B. *Prog. Brain Res.*, 116, 441-458 (1998)
- Koroshetz & Moskowitz, *Trends in Pharmacol. Sci.*, 17, 227-233  
(1996)
- Dunn, C.D.R., *Scrip Reports*, PJB Publications, Richmond 1995  
Chapter Two, pp. 61-90, Chapter Four, pp 149-159
- Arrowsmith, J.E. et al., *Stroke*, 29, 2357-2362 (1998)
- DeVry, *Psychopharmacology*, 121, 1-26 (1995)
- Matsuyama, S., *Brain Res.*, 728, 175-180 (1996)
- DeVry, *Drugs of the Future*, 22, 341-349 (1997)
- Schechter et al., *Serotonin*, Vol. 2, No. 7, 299-309 (1997)

Lazareno et al., *Br. J. Pharmacol.*, 109, 1120-27 (1993)  
Coyle, *Harvard Rev. Psychiatry*, 3, No. 5, 241-253 (1996)  
Lucki et al., *J. Pharma. & Experimental Ther.*, 228 (No. 1)  
133-139 (1983)  
Smith, L.M. et al., *Pharmacol. Biochem Behavior*, 24, 1513-19,  
(1986)

Copies of the above-cited references are enclosed herewith.

Respectfully submitted,

  
Rebecca R. Barrett  
Reg. No. 35,152

Date: January 31, 2001  
Telephone: (610)902-2646